Vicore has carried out directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share, raising gross proceeds of SEK 500 million
Stockholm, 9 June 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) has completed directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share (the “Directed Issue”), through which the Company receives SEK 500 million before transaction costs. The subscription price was determined through an accelerated bookbuilding procedure conducted by Carnegie Investment Bank AB (publ) (”Carnegie”), Pareto Securities AB (“Pareto Securities”), Van Lanschot Kempen N.V. (“Van Lanschot Kempen”) and Zonda Partners AB (“Zonda”) as Joint Bookrunners (together the “Joint Bookrunners”). The Directed Issue was oversubscribed with a wide range of Swedish and international institutional investors participating, including OrbiMed, Suvretta Capital Management LLC, HBM Healthcare Investments, HealthCap VII L.P., the Fourth AP Fund, the Third AP Fund, Swedbank Robur Fonder and SEB Investment Management.
